These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11193851)

  • 1. Alanine scanning of VIP. Structure-function relationship for binding to human recombinant VPAC1 receptor.
    Nicole P; Rouyer-Fessard C; Couvineau A; Drouot C; Fulcrand P; Martinez J; Laburthe M
    Ann N Y Acad Sci; 2000; 921():352-6. PubMed ID: 11193851
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.
    Nicole P; Lins L; Rouyer-Fessard C; Drouot C; Fulcrand P; Thomas A; Couvineau A; Martinez J; Brasseur R; Laburthe M
    J Biol Chem; 2000 Aug; 275(31):24003-12. PubMed ID: 10801840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequences (103-110) and (116-120) of the rat secretin receptor are implicated in secretin and VIP recognition.
    Robberecht P; Di Paolo E; Moguilevsky N; Bollen A; Waelbroeck M
    Ann N Y Acad Sci; 2000; 921():362-5. PubMed ID: 11193853
    [No Abstract]   [Full Text] [Related]  

  • 4. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different domains of the VIP receptors modulate agonist affinity and intrinsic activity.
    Juarranz MG; Van Rampelbergh J; Gourlet P; Waelbroeck M; Robberecht P
    Ann N Y Acad Sci; 2000; 921():395-9. PubMed ID: 11193863
    [No Abstract]   [Full Text] [Related]  

  • 7. Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP.
    Tan YV; Couvineau A; Laburthe M
    J Biol Chem; 2004 Sep; 279(37):38889-94. PubMed ID: 15247290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure.
    Vertongen P; Solano RM; Juarranz MG; Perret J; Waelbroeck M; Robberecht P
    Peptides; 2001 Sep; 22(9):1363-70. PubMed ID: 11514016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P; Solano RM; Perret J; Langer I; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Eur J Biochem; 1999 Oct; 265(1):449-56. PubMed ID: 10491203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for multiple rat VPAC1 receptor states with different affinities for agonists.
    Busto R; Juarranz MG; De Maria S; Robberecht P; Waelbroeck M
    Cell Signal; 1999 Sep; 11(9):691-6. PubMed ID: 10530878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction.
    Solano RM; Langer I; Perret J; Vertongen P; Juarranz MG; Robberecht P; Waelbroeck M
    J Biol Chem; 2001 Jan; 276(2):1084-8. PubMed ID: 11013258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cysteine residues in the N-terminal extracellular domain of the human VIP 1 receptor for ligand binding. A site-directed mutagenesis study.
    Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
    Ann N Y Acad Sci; 1996 Dec; 805():585-9. PubMed ID: 8993444
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
    Langer I; Perret J; Vertongen P; Waelbroeck M; Robberecht P
    Cell Calcium; 2001 Oct; 30(4):229-34. PubMed ID: 11587546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a CHO cell clone stably expressing the recombinant human VIP-1 receptor.
    Gaudin P; Couvineau A; Maoret JJ; Rouyer-Fessard C; Laburthe M
    Ann N Y Acad Sci; 1996 Dec; 805():570-3. PubMed ID: 8993441
    [No Abstract]   [Full Text] [Related]  

  • 18. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
    Couvineau A; Rouyer-Fessard C; Laburthe M
    Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
    Langer I; Robberecht P
    Cell Signal; 2005 Jan; 17(1):17-24. PubMed ID: 15451021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.